Is low-to-moderate alcohol consumption beneficial for longevity?

PA **peterattiamd.com**/low-to-moderate-alcohol-consumption-and-longevity

Peter Attia January 3, 2024



Figure: Mortality risk relative to non-drinkers by number of alcoholic drinks consumed per day for men (solid line) and women (dashed line). Plot shows means and 99% confidence intervals for data pooled from 32 data curves (men) and 16 data curves (women). Risk is shown relative to non-drinkers, represented by the horizontal line. From Di Castelnuovo et al., 2006.

Alcohol presents a paradox. On one hand, it is linked to over three million deaths per year globally and fuels societal issues such as intimate-partner violence and traffic accidents. On the other hand, it's not entirely a one-dimensional narrative of harm – potential benefits are intertwined with the undeniable perils. According to epidemiological studies, moderate daily consumption of alcohol – a common global practice – has been associated with a *reduced* risk of several serious diseases including type 2 diabetes, ischemic heart disease, coronary heart disease (CHD), and stroke, leading to decreased overall mortality rates. How do we resolve these findings with alcohol's unambiguous toxicity? And how do we draw the line between healthy and unhealthy drinking patterns?

The J-shaped Curve Theory

The relationship between alcohol consumption (i.e., ethanol, the form of alcohol we drink) and human health is complex. The dichotomy between benefits and harms forms the basis for the so-called “J-shaped curve” theory, which suggests that light to moderate drinking might offer some protection against specific health conditions such as CHD and may reduce cardiovascular disease (CVD) mortality. (Picture a big “J” as the mortality curve where the nadir of mortality is not actually the very left of the graph–zero alcohol consumption–but slightly to the right with modest intake.) This theory, however, is still a matter of scientific dispute.

A number of studies have contributed to this theory. For example, an extensive analysis of data from 333,247 National Health Interview Survey participants (1997-2009) found that, compared with lifetime abstainers, those who were “light” (≤3 drinks/week) or “moderate” (4-14 drinks/week for men or 4-7 drinks/week for women) alcohol consumers had a reduced risk of mortality from CVD (HR=0.74, 95% CI: 0.69-0.80 and HR=0.71, 95% CI: 0.64-0.78 for light and moderate drinkers, respectively). These groups also demonstrated decreased mortality from all causes (HR=0.79, 95% CI: 0.76-0.82 and HR=0.78, 95% CI: 0.74-0.82, respectively).

According to a meta-analysis of 34 prospective studies involving over one million people and nearly 100,000 deaths, men consuming ≤4 drinks and women ≤2 drinks daily have lower mortality rates than non-drinkers. The lowest mortality risk was observed among individuals consuming an average of one half drink per day, with a maximum protective effect of 18% (99% CI: 13%-22%) for women and 17% (99% CI: 15%-19%) for men. However, above approximately three drinks per day for women or four drinks per day for men, the effect on mortality reverses, such that drinking is associated with greater risk than abstainers, supporting the J-shaped correlation between alcohol and total mortality (see figure below),



Figure: Mortality risk relative to non-drinkers by number of alcoholic drinks consumed per day for men (solid line) and women (dashed line). Plot shows means and 99% confidence intervals for data pooled from 32 data curves (men) and 16 data curves (women). Risk is shown relative to non-drinkers, represented by the horizontal line. From Di Castelnuovo et al., 2006.

Ethanol is Toxic

At the same time, the *negative* health impacts of *heavy* alcohol consumption are well-documented and undeniable and primarily stem from ethanol's toxicity. A meta-analysis by Stockwell et al. of 87 studies revealed that high-volume drinking (45-65 g/day, or between 3-5 drinks/day) is associated with a 24% higher risk of all-cause mortality (RR=1.24, 95% CI: 1.12-1.37), whereas higher-volume drinking (≥65 g/day, or >5 drinks/day) had a 44% higher risk of all-cause mortality (RR=1.44, 95% CI: 1.30-1.60). But it's not just epidemiology that supports this view. Alcohol in high quantities can be a potent catalyst for health deterioration, an observation that has been supported by a number of Mendelian randomization (MR) studies as well. (For a primer on the logic behind Mendelian randomization and how it facilitates causal inference from observational data, see this article).

For instance, a 2022 study genotyped 150,722 Chinese adults enrolled from 2004 to 2008 to look into the relationship between alcohol consumption and cancer risk. Interestingly, there are two common genetic variants found in East Asian populations that influence alcohol tolerance and are linked to lower alcohol consumption, described below. Since these genes are randomly "assigned" at birth, and don't impact cancer initiation, we can use their presence (less drinking, on average) or absence (more drinking, on average) as a proxy for a prospective randomized experiment.

1. **ALDH2 (aldehyde dehydrogenase 2):** This gene produces an enzyme responsible for breaking down acetaldehyde, a toxic substance and a human carcinogen that is produced during the metabolism of alcohol. An East Asian-specific loss-of-function (LOF) variant of the ALDH2 gene (rs671 G>A) significantly reduces the breakdown of acetaldehyde, causing a reaction often known as “alcohol flush response,” an unpleasant reaction associated with lower consequent alcohol consumption.
2. **ADH1B (alcohol dehydrogenase 1B):** This gene produces an enzyme involved in the first step of alcohol metabolism, the conversion of ethanol to acetaldehyde. A gain-of-function (GOF) variant in the ADH1B gene (rs1229984 G>A) speeds up the formation of acetaldehyde from alcohol. Again, the accelerated conversion can lead to a buildup of acetaldehyde and the “flush” response.

Over an 11-year follow-up, 9,339 participants developed cancer, and the researchers verified that the LOF variant in ALDH2 and the GOF variant in ADH1B indeed strongly correlated with lower alcohol consumption. Again, because genetic variants are assumed to be *randomly* distributed, the patterns of alcohol intake resulting from these variants can also be assumed to be randomized, effectively allowing us to determine how alcohol intake affects cancer risk by using genetic variants that *impact* alcohol intake as proxies.

Among men, those with two copies of the ALDH2 variant were 31% less likely to develop various cancers compared to men with two normal copies of this gene (HR=0.69, 95% CI: 0.53-0.90). For ADH1B, those with one or two copies of the GOF variant had a 20% and 25% reduction in risk of these cancers, respectively, compared to those with two normal gene copies, as reflected by HRs of 0.80 (95% CI: 0.69-0.93) and 0.75 (95% CI: 0.64-0.87). Much of this effect was specifically related to reduced risk of head and neck cancer and esophageal cancer. These findings ultimately support the idea that alcohol consumption causally contributes to the development of upper aerodigestive tract cancers, and while an effect was only seen in males, this is likely because only 2% of women in the study were found to drink alcohol regularly, and thus the study was underpowered to find any association between alcohol and cancer in females.

Further, the health risks associated with alcohol do not appear to be confined to heavy drinkers alone. Another recent MR study, by Biddinger et al., revealed that a one-standard deviation increase in genetically predicted alcohol consumption could lead to a 1.3-fold (95% CI: 1.2-1.4) higher risk of hypertension and a 1.4-fold (95% CI: 1.1-1.8) higher risk of coronary artery disease. Importantly, it found that light to moderate alcohol consumption was *not* associated with reduced CV risk, but was, in fact, associated with a small *increase* in risk of hypertension and coronary artery disease.

So although the J-curve relationship may imply benefits of modest alcohol consumption in the context of epidemiologic studies, it’s important not to overlook that ethanol is indeed a toxic substance. A study published in Alcohol Research & Health highlighted the numerous detrimental effects that result from alcohol metabolism, including oxygen deficiency in the liver, the formation of harmful byproducts from alcohol metabolism, and the production of reactive oxygen species, all of which can, in turn, cause damage to entire tissues and impair other metabolic processes.

How can alcohol simultaneously be good and bad for health?

All of the data presented thus far lead inevitably to the question: *how?* How can so many studies find a benefit to low or moderate alcohol consumption, despite its objective toxicity even at low doses? Of course, one explanation is flawed science, and as we'll see below, alcohol research is certainly guilty on this front. But we also have reason to suspect that there's more to the story – that although the direct, biochemical effects of *ethanol* are toxic, other aspects of *alcohol consumption – either other compounds in the drink and/or the manner in which it is consumed* – might be beneficial.

As we see from the Biddinger et al. MR study, ethanol's toxicity profile is not linear: as alcohol intake increases linearly, health risks can increase exponentially, and low levels of consumption may therefore come with low risk. If the risk from the ethanol itself is low enough, it's conceivable that other aspects of alcohol consumption – its prosocial effects, the effects of non-ethanol components of a drink, or otherwise – might offer benefits that *outweigh* the negative impact of ethanol, thus giving rise to the apparent J-curve relationship. This would imply that the relationship between alcohol intake and health does not solely depend on the quantity of alcohol (i.e., ethanol) consumed but also on other factors such as the *type* of alcohol consumed and the *context* in which it is consumed. In other words, the relationships between alcohol and health are more intricate than the J-curve might suggest, necessitating a more nuanced view of alcohol's effects.

Red Wine: In Vino Veritas?

Many people believe that red wine does a uniquely good job of increasing the ratio of benefits to risks when it comes to alcohol consumption. The health advantages of red wine have primarily been attributed to its rich content of antioxidants. Resveratrol, a polyphenol found in the skin of red grapes, has received the most attention in this respect and has been proposed to prevent CHD, though, as we will discuss below, much of this research has since been debunked. Still, resveratrol is far from the only antioxidant or bioactive molecule present in red wine that might impart some benefit to health, so how well does evidence support the idea that red wine is a unique elixir of life?

This concept first emerged in the 1970s with the discovery of what was termed the "French paradox." Despite maintaining a diet high in saturated fats, the French reportedly had a remarkably low incidence of heart disease, about 42% less than their U.S. counterparts. This surprising fact led researchers to theorize that the routine consumption of red wine could be a contributing factor.

Additional studies have since lent some credibility to this theory. A 2022 systematic review and meta-analysis of longitudinal studies found that moderate drinking of red and white wine was associated with a 28% reduced risk of cognitive deterioration, as reflected by a pooled relative risk of 0.72 (95% CI: 0.63-0.80). Another study examined the impact of moderate red wine consumption on gene expression in a group of cloistered nuns, reporting that after two weeks of controlled red wine intake, participants exhibited increased expression of longevity-related

genes. A narrative review of 24 observational studies further supported these results, showing that moderate wine consumption – especially as part of a Mediterranean diet – could confer health benefits.

The CASCADE Trial

In addition to citing epidemiological evidence and *in vitro* studies, many supporters of the red wine theory point to results from the CASCADE trial, the first long(ish)-term randomized trial and most extensive study in the field of alcohol consumption and health. Conducted over two years, the trial followed 224 patients with type 2 diabetes who were abstaining from alcohol at baseline. Participants were randomly assigned to consume either 150 mL (roughly one glass) of mineral water, white wine, or red wine with their evening meal while adhering strictly to a Mediterranean diet but without any calorie constraints. Each participant was aware of their treatment allocation, and the study investigated alterations in lipids, glycemic control parameters, blood pressure, quality of life, and other health metrics.

Compared to the group consuming water alongside the Mediterranean diet, those who drank red wine had statistically significant improvements in several of the metrics measured. Their levels of HDL-C increased by 0.05 mmol/L (2.0 mg/dL) and their total cholesterol to HDL-C ratio decreased by 0.27. Additionally, those drinking red wine had a slight reduction in some of the components of metabolic syndrome compared to the water group. For instance, both red and white wine resulted in a decrease in fasting blood glucose levels, though the change was only significant for the white wine group at a decrease of 1.0 mmol/L (17.2 mg/dL) (95% CI: 1.60- 0.3 mmol/L [28.9-5.5 mg/dL]; P = 0.004). Apart from these metrics, there were no notable differences across the three groups in areas such as blood pressure, adiposity, liver function, or overall quality of life.

The Many Problems with Wine and Alcohol Research

At first look, results from CASCADE and epidemiology studies may appear to bolster the notion that moderate wine consumption (within the context of a healthy diet) appears safe for individuals with well-controlled diabetes, and might marginally reduce cardiometabolic risk. Forget all that exercise nonsense – pour me a cab! But of course, the story isn't that simple. Research on wine and alcohol more generally is rife with flaws that can lead to misinterpretation of results.

1. Limitations of the RCTs

Several short-term randomized trials have attempted to investigate the effects of alcohol on various potential mediators of health and longevity effects. Most of these have involved a small number of participants and have predominantly focused on assessing parameters such as changes in HDL-C or inflammation markers. They do not typically address hard clinical endpoints such as cardiovascular events or cancer diagnoses. These studies thus can't provide the comprehensive understanding that a large, long-term RCT could offer. For

instance, the nun study mentioned above included merely nine participants, lasted two weeks, and evaluated readouts (i.e., the expression of longevity genes) that do not clearly translate into health outcomes.

The CASCADE trial is, disappointingly, yet another example of these limitations. When we look more specifically at the lipid parameters that differed between the red wine group and the water group, we see that the changes are so small that they don't hold great clinical value. Moreover, even if they *were* clinically significant, changes in HDL-C levels do not indicate improvements in HDL particle functionality, and, as trials of HDL-raising medications have shown, increased HDL-C alone does not improve clinical outcomes. For these reasons, even a more substantial decrease in the ratio between total cholesterol and HDL-C would have no clinical significance. Similarly, measures of glucose control did not show meaningful or clinically relevant changes. Fasting plasma glucose – the blood sugar level after an overnight fast – is subject to transient fluctuations and could be affected by factors such as an acute hypoglycemic effect caused by ethanol intake. Though the more reliable measure of glycated hemoglobin (HbA1c) was observed to decrease over the course of the study, the three groups did not exhibit significant *differences* in how this metric changed over time.

The observation of an HbA1c decrease in *all three* groups is indicative of another common problem in alcohol RCTs, including CASCADE: the challenge of interpreting findings when multiple interventions are introduced simultaneously. In addition to being assigned to white wine, red wine, or water, the subjects in the CASCADE trial also adopted a Mediterranean diet. While the authors singled out and highlighted changes in the red wine group, the fact that all three groups demonstrated a reduction in HbA1c and a temporary improvement in their lipid profiles indicates that the *Mediterranean diet* – not the assigned beverage – was more likely responsible for many of the observed benefits. Indeed, numerous studies have demonstrated similar associations between the Mediterranean diet and these health metrics.

Ultimately, small, poorly designed, short-term clinical trials and the limited longer-term trials have typically focused on clinically insignificant (and, thus, irrelevant) metrics and have failed to provide us with valuable insights into the effects of alcohol on health. Until a large, long-term clinical trial is conducted, with hard clinical outcomes as the key measures, our understanding of alcohol's effects on health will remain incomplete.

2. Limitations of Observational Research

Large-scale, long-term randomized controlled trials (RCTs) on alcohol consumption are often considered prohibitively challenging due to various ethical, financial, and logistical reasons. As such, much of our understanding relies on observational studies which, despite offering valuable clues, are subject to biases and are unable to definitively establish causation.

1. **Defining "abstainers"**

One critical source of bias in observational alcohol research, as detailed by Stockwell et al. in their 2016 publication described previously, centers around how "abstainers" are classified in many of the studies reporting a J-curve relationship between alcohol consumption and health outcomes. This classification, they argue, might unintentionally introduce a "sick-quitter" bias

into the results – a situation in which individuals who have quit drinking alcohol – often due to health problems that are or are not associated with alcohol – are lumped together with lifetime abstainers in the study's control group. These individuals are likely less healthy than *both* the lifetime abstainers and moderate drinkers, potentially leading to an overestimation of health issues among abstainers and thus making moderate drinking appear healthier by comparison. In their re-analysis of longitudinal studies focused on alcohol and mortality, Stockwell et al. discovered that after adjusting for biases, including the "sick-quitter" bias, the alleged protective effects of alcohol were completely abolished.

2. **Survivor bias**

Another key bias that can influence the outcomes of observational studies on alcohol and health is known as the "survivor bias." This bias emerges when the healthiest members of a population disproportionately outlive their peers, leading to a distorted overrepresentation of healthier individuals within the studied group over time. In the context of alcohol research, "survivor bias" can present itself when the sicker moderate drinkers die off earlier, leaving a healthier cohort of moderate drinkers to be studied.

This bias can significantly distort results because the surviving moderate drinkers may not be representative of all moderate drinkers. They may be inherently healthier, or have other factors such as better diet or exercise habits that contribute to their longevity. This bias is especially problematic in longitudinal studies, where researchers follow the same group of individuals over a long period of time. As the sicker individuals within the moderate drinking cohort continue to die off, an increasingly healthier set of individuals comprises the remaining group who ultimately finish the study. This can lead to an underestimation of the potential health risks associated with moderate drinking and may falsely suggest a protective effect of alcohol.

3. **Health confounds and the "moderate drinker"**

Confounding variables – such as socioeconomic status, exercise habits, and dietary patterns – also play an integral role in determining health outcomes. One might misattribute the ostensibly better health of moderate drinkers to their alcohol consumption rather than to other health-promoting factors that potentially covary with moderate alcohol intake. In other words, the health benefits attributed to moderate drinking may instead be a result of overall healthier lifestyle choices and responsible behavior exhibited by such drinkers, and inconsistent results can arise due to variability across studies in the confounds for which they adjust. Further, this tendency for confounding could conceivably play a larger role in studies of red wine than in studies of alcohol more generally, as red wine consumption tends to be more closely associated with socioeconomic status and other relevant variables, such as a Mediterranean diet, than total alcohol intake. This is likely why we don't have any data for the health benefits for vodka and Red Bull or Jager shots – such drinking patterns are categorically not associated with other healthy behaviors (trust me, I have a vague recollection).

4. **Measuring alcohol consumption**

The struggle to accurately measure alcohol consumption increases the potential for error in these studies, especially when considering variations in drinking patterns, such as binge versus moderate drinking. One glass of wine six nights out of every week is likely to have very different effects on long-term health than six glasses of wine one night out of every week, but on a survey asking participants to estimate their total number of weekly drinks, the two patterns are indistinguishable.

Even estimating total alcohol intake, regardless of pattern, is not an easy task. The enormous variability in drink volumes and alcohol concentrations means that accurate estimation of intake requires careful measurement and concentration calculations, which is hardly a common practice and, in the setting of a bar or restaurant, is virtually impossible. Additionally, asking individuals to recall their drinking behavior over a short period, which is often subject to bias in itself, may not reflect their usual drinking patterns over longer time spans.

5. **Inconsistencies in findings**

It's also important to note that conclusions regarding the J-shaped correlation have generally been inconsistent, and the effects of alcohol consumption vary across studies and across health outcomes under investigation. For certain health outcomes, like some cancers, the relationship with alcohol consumption appears to be direct and linear. In contrast, a J-shaped correlation has been reported for diseases (like cirrhosis of the liver) for which we lack a credible biological basis for any protective effect of alcohol. These illogical findings highlight the influence of biases and confounds.

A 2023 systematic review and meta-analysis by Zhao et al., which adjusted for the issues outlined above, found no associated reduction in mortality, and as we've seen, Mendelian randomization studies generally haven't shown that moderate drinking promotes cardiovascular health.

3. A Note on Resveratrol

As mentioned above, the fact that low or moderate alcohol intake has been observed to benefit health and longevity can be explained in three ways: 1) other compounds present in specific types of alcohol, 2) flawed science, and 3) indirect effects dependent on contextual variables. As we've seen, evidence for explanation #1 is currently very limited, yet the red wine narrative – and specifically the resveratrol narrative – continues to capture popular fantasies. So before moving on to explore explanation #3, let's take a minute to place the resveratrol story where it belongs: under the umbrella of "flawed science."

The idea of resveratrol as a panacea for aging swept across the scientific community largely due to a paper which demonstrated that metabolically ill mice exhibited extended longevity when given resveratrol – a phenomenon linked to the activation of proteins known as sirtuins. However, as I discussed with Dr. Richard Miller on *The Drive*, this study has been severely misinterpreted.

Critically, these mice were not simply aging but were also being subjected to an unusual diet consisting of 60% coconut oil – designed to drive a pathological process in which the animals' livers become so engorged with fat that it ultimately leads to death through chest compression and lung collapse. (Yes, you read that correctly.) While the study noted a significant increase in median lifespan with resveratrol, *maximum* lifespan indicators showed no benefits from the compound. Further, median lifespan extension was only observed for the animals on this highly toxic diet; mice not subjected to the unhealthy diet showed no extension of life. Thus, the conclusion from the original experiment – that resveratrol was a longevity compound – does not hold up under closer scrutiny. In fact, it merely served to alleviate a specific, unusual lipid toxicity, rather than genuinely slow the aging process.

Indeed, in the study's aftermath, the Intervention Testing Program (ITP) further investigated the effects of this compound on lifespan by administering it in considerably higher doses to mice of two different age groups – 12 months and 4 months, corresponding roughly to humans in their late 50s and mid-20s. Despite the hefty doses, the study found no positive impact on either median or maximum lifespan, countering the notion of resveratrol as a general lifespan extender for mice on a normal diet. Moreover, this study established that resveratrol, often touted as the star ingredient of wine, *was not even a significant component of this beverage*. To match the mouse dose of resveratrol used in the studies, one would have to consume around 600 bottles of wine a day – not an approach I would suggest for anyone trying to survive until tomorrow, let alone to age 100+.

Resveratrol therapeutic attempts in humans have also been disappointing, in large part because it is rapidly metabolized in the human body, limiting therapeutic potential even if it *did* have anti-aging effects. Upon consumption, resveratrol is quickly converted into various metabolites by the liver and intestines, which are then excreted, meaning it has low bioavailability – the proportion of a drug or other substance that enters the circulation when introduced into the body and is able to have an active effect. This rapid metabolism means that even if a large dose is ingested, the concentration of resveratrol in the blood and tissues will remain too low to have significant biological effect. So, while oral absorption of resveratrol in humans is about 75%, due to extensive metabolism in the intestine and liver, the bioavailability is considered to be less than 1%.

Taken together, these data show that there is zero reason to consume resveratrol in any form, but especially in the minuscule doses found in red wine.

Pattern Matters

The nonlinear relationship between alcohol consumption and negative health effects – at least in some contexts – means that at low levels of intake, health risks are also low, opening the door for the possibility that other effects of alcohol consumption may result in a modest positive effect. Though benefits based on the type of alcohol remain possible, reliable supporting evidence is virtually nonexistent. But what about benefits based on the *context* of alcohol consumption?

1. The Mediterranean Alcohol Drinking Pattern

The Mediterranean Alcohol Drinking Pattern (MADP), characterized by routine, measured consumption of red wine, typically at meals, and an avoidance of over-drinking or binge drinking episodes, has emerged as a viable harm-reduction strategy. Multiple Mediterranean cohorts have corroborated the positive impact of the Mediterranean alcohol consumption pattern on mortality. Indeed, several prospective studies have demonstrated that the health benefits derived from following a Mediterranean diet far outweigh those obtained from the consumption of any single nutrient, and in this context, low to moderate consumption of wine is unlikely to cause harm. This intricate interaction between diet and alcohol likely involves multiple interconnected mechanisms. For instance, the antioxidants found in both the Mediterranean diet generally and wine could potentially mitigate the carcinogenic effects of ethanol. While such studies can not disentangle the role of diet versus alcohol consumption and the evidence is sparse, it points towards a reduction in overall mortality risk with high adherence to a Mediterranean diet supplemented by the MADP.

In the context of the MADP, alcohol consumption may bring about certain benefits for some individuals, though these benefits may not be directly linked to the substance itself but rather to its stress-reducing and prosocial effects. In some cases, moderate alcohol consumption can facilitate social interaction and bonding or help individuals to relax and unwind. This can have positive physiological effects, such as reducing stress levels and promoting a sense of well-being. For some people, these benefits may outweigh the potential harms of moderate drinking, particularly if they consume alcohol responsibly and maintain a generally healthy lifestyle. Of note, these stress-reducing and prosocial effects may also underlie the perceived “special” benefit of red wine – for evening relaxation or a dinner party with friends, it’s probably safe to say that most would opt for a little wine over tequila shots or Long Island iced tea.

However, it’s crucial to note that these benefits are not universal and can vary significantly from person to person. For many individuals, alcohol consumption can be antisocial and harmful, leading to negative behavioral changes, interpersonal issues, and potential addiction. These risks can be present at any level of consumption and with any type of alcohol and may far outweigh any potential benefits. Therefore, the potential benefits and harms of alcohol consumption must be considered on an individual basis, taking into account a person’s unique physiological responses, social context, and behavioral tendencies.

2. Timing of alcohol consumption

Another important aspect of alcohol intake patterns is the timing of consumption relative to sleep. Alcohol produces sedative effects, acting as a GABA agonist and hastening the onset of sleep. However, this rapid descent into unconsciousness should not be mistaken for authentic sleep, which involves specific restorative processes in the brain.

As explained on the podcast by Dr. Matt Walker, alcohol affects sleep in two significant ways. Firstly, it fragments sleep, leading to numerous awakenings throughout the night, often too brief to be remembered yet consequential enough to disrupt our sleep physiology. Secondly, it impedes REM sleep, the crucial stage associated with memory consolidation and emotional processing. This results in waking up feeling unrestored, even after seemingly adequate sleep.

The exact mechanism causing sleep disruption from alcohol isn't fully understood, but research suggests the byproducts of alcohol metabolism, specifically aldehydes, might play a role. Aldehydes can block the brain's ability to generate REM sleep, leaving us unrefreshed upon waking.

Ultimately, this means that if you're going to drink, creating as much distance from sleep – at least three hours – is the safest course of action. Of note, this may also contribute to the appearance that wine is healthier than other alcoholic beverages, as many who consume wine do so primarily with dinner as opposed to having wine nightcaps.

Conclusion

Data demonstrating a correlation between moderate alcohol consumption and beneficial health outcomes may make an attractive case, yet we should be wary of endorsing alcohol consumption purely for its purported health benefits. The proposition that daily alcohol, and especially red wine consumption, could potentially improve cardiovascular health should be balanced with an understanding that any health advantage over complete alcohol abstinence is yet to be definitively established.

Moreover, no one should mistake alcohol, in general, as a health-enhancement tool. Ethanol is a biochemically toxic substance – full stop – and no level of ethanol consumption can be deemed entirely "safe" or "healthy." A more judicious viewpoint would be that any potential health benefits derived from moderate alcohol intake are more likely to be a byproduct of a lifestyle that includes limited wine consumption. Consuming alcohol (preferably red wine) modestly, ideally with meals and as far away from bedtime as possible, may deter more unhealthy drinking patterns and reduce the chance of harm, but those who do not already drink should not start doing so out of a misguided hope that it will make them healthier.

The bottom line is that the link between alcohol consumption and health outcomes is a labyrinth of intricacies, influenced by variables like genetic makeup, lifestyle habits, and the nature and quantity of alcohol consumed. And while ongoing research endeavors are geared towards untangling these complexities, it's paramount to convey that promoting alcohol consumption should be primarily framed within a harm-reduction context rather than as a health-enhancement strategy.

For a list of all previous weekly emails, click here.

podcast | website | ama